Skip to main
SION

SION Stock Forecast & Price Target

SION Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 83%
Buy 0%
Hold 0%
Sell 17%
Strong Sell 0%

Bulls say

Sionna Therapeutics Inc. is positioned with a potentially significant market opportunity in the cystic fibrosis treatment landscape, particularly if its innovative NBD1 stabilizers demonstrate enhanced efficacy compared to the standard of care, Trikafta. The company's proprietary combination SION-451 and add-on therapy SION-719 have estimated worldwide revenue potentials of $3.2 billion and over $900 million, respectively, even under conservative market penetration assumptions. As Sionna focuses on directly stabilizing previously undruggable targets while enhancing patient outcomes, it strengthens the rationale for a positive financial outlook on its stock.

Bears say

Sionna Therapeutics Inc faces significant risks that could adversely impact its financial outlook, primarily due to potential safety issues, weaker-than-expected drug efficacy, and challenges related to pharmacokinetics and pharmacodynamics properties of its candidates. There is a heightened concern regarding the commercial uptake of existing therapies like Kaftrio, as well as increasing competition and pricing pressures, which could diminish revenue generation capabilities. Additionally, the company may encounter regulatory hurdles or setbacks in clinical trials that could further jeopardize its pipeline programs and overall financial performance.

SION has been analyzed by 6 analysts, with a consensus rating of Buy. 83% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sionna Therapeutics Inc (SION) Forecast

Analysts have given SION a Buy based on their latest research and market trends.

According to 6 analysts, SION has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sionna Therapeutics Inc (SION)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.